Sarepta Therapeutics (SRPT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Sarepta Therapeutics (SRPT) Healthcare & Pipeline Overview

Sarepta Therapeutics, Inc. is a leading biopharmaceutical company dedicated to developing RNA-targeted therapeutics and gene therapies for rare diseases, particularly Duchenne muscular dystrophy, leveraging advanced exon-skipping technology and a robust pipeline of innovative products.

What Is the Investment Thesis for SRPT?

The company has a market capitalization of $2.17B and a P/E ratio of 37.17, reflecting investor confidence in its growth potential. Key value drivers include the successful commercialization of EXONDYS 51 and VYONDYS 53, which have established a revenue stream, alongside the anticipated approval of AMONDYS 45 and other pipeline candidates. Sarepta's gross margin stands at 62.4%, significantly above the industry average, indicating efficient cost management and pricing power. Upcoming catalysts include potential regulatory approvals and clinical trial results that could expand its product offerings and market share. However, risks such as regulatory hurdles and competitive pressures from peers like ImmunityBio, Inc. (IBRX) and Beam Therapeutics Inc. (BEAM) must be monitored closely.

Based on FMP financials and quantitative analysis

SRPT Key Highlights

Market capitalization of $2.17B reflects strong investor interest in rare disease therapeutics.

• P/E ratio of 37.17 indicates a premium valuation compared to industry peers, driven by growth expectations.
• Gross margin of 62.4% highlights operational efficiency and strong pricing power in the biotechnology sector.
• Profit margin of 3.0% demonstrates initial profitability amidst significant R&D investments.
• Beta of 0.28 suggests lower volatility compared to the broader market, appealing to risk-averse investors.

Who Are SRPT's Competitors?

SRPT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SRPT's Key Strengths?

Innovative product pipeline targeting rare diseases with high unmet needs.

• Established revenue from FDA-approved therapies.
• Strong partnerships enhancing research capabilities and market reach.
• Expertise in RNA-targeted therapeutics and gene therapy technologies.

What Are SRPT's Weaknesses?

Dependence on a limited number of products for revenue generation.

• High R&D costs associated with developing complex therapies.
• Potential for regulatory hurdles impacting product approvals.
• Market competition from established and emerging biotechnology firms.

What Could Drive SRPT Stock Higher?

SRPT catalyst: Potential FDA approval of AMONDYS 45 in late 2026 could significantly expand Sarepta's product offerings.

• Clinical trials for SRP-9001 and SRP-9003 are progressing, with results expected to drive future growth.
• Strategic collaborations with F. Hoffman-La Roche Ltd and others are enhancing research and development capabilities.
• Increased awareness and advocacy for Duchenne muscular dystrophy may drive demand for existing and future therapies.
• Expansion of the company's research initiatives into limb-girdle muscular dystrophies is underway.

What Are the Key Risks for SRPT?

Financial-distress signal — its Altman Z-Score of -0.01 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-10.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles could delay product approvals and impact revenue timelines.
• Competition from other biotechnology firms could pressure market share and pricing.
• Adverse clinical trial results may hinder pipeline development and investor confidence.
• Dependence on a limited number of products for revenue generation poses financial risks.
• Changes in healthcare policies and reimbursement practices could affect market access.

What Are the Growth Opportunities for SRPT?

• Growth opportunity 1: Sarepta's ongoing development of AMONDYS 45, targeting exon 45 of the dystrophin gene, positions the company to capture a significant share of the DMD treatment market.
• Growth opportunity 2: The expansion of the SRP-9001 micro-dystrophin gene therapy program offers a promising avenue for treating DMD patients. With the global gene therapy market projected to grow at a CAGR of 25% through 2028, successful clinical trials could lead to rapid adoption and significant market penetration.
• Growth opportunity 3: Sarepta's collaboration with F. Hoffman-La Roche Ltd enhances its research capabilities and accelerates the development of novel therapies. This partnership could yield innovative treatments for other rare genetic disorders, expanding Sarepta's product pipeline and market presence.
• Growth opportunity 4: The company's focus on limb-girdle muscular dystrophies through the SRP-9003 program taps into an underserved patient population. The limb-girdle muscular dystrophy market is anticipated to grow to $1.5 billion by 2027, providing Sarepta with an opportunity to diversify its therapeutic offerings.
• Growth opportunity 5: Increasing awareness and advocacy for rare diseases are driving demand for effective treatments. As Sarepta continues to innovate and expand its product portfolio, it stands to benefit from heightened patient and physician interest, potentially leading to increased sales and market share.

What Threats Does SRPT Face?

• Intense competition from other biotechnology companies.
• Regulatory changes affecting drug approval processes.
• Market volatility impacting funding and investment in biotech.
• Potential adverse clinical trial results affecting product pipeline.

What Are SRPT's Competitive Advantages?

• Strong intellectual property portfolio protecting innovative therapies.
• Established market presence with FDA-approved products generating revenue.
• Collaborative partnerships with leading research institutions enhancing credibility.
• Expertise in RNA-targeted therapeutics and gene therapies differentiating from competitors.
• Commitment to addressing rare diseases with significant unmet medical needs.

What Does SRPT Do?

Founded in 1980 and headquartered in Cambridge, Massachusetts, Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that specializes in the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities aimed at treating rare diseases. The company has carved a niche in the biotechnology sector with its innovative approach to addressing Duchenne muscular dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration. Sarepta's flagship products include EXONDYS 51 and VYONDYS 53, both designed to treat patients with specific mutations in the dystrophin gene that are amenable to exon skipping. In addition to these marketed products, Sarepta is advancing a robust pipeline that includes AMONDYS 45, SRP-5051, SRP-9001, and SRP-9003, targeting various aspects of DMD and other muscular dystrophies. The company has established collaborative agreements with prominent organizations such as F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, and Duke University, enhancing its research capabilities and market reach. With a workforce of approximately 1,372 employees, Sarepta is positioned as a key player in the biotechnology landscape, focused on delivering transformative therapies to patients with rare genetic disorders.

What Products and Services Does SRPT Offer?

• Develop RNA-targeted therapeutics and gene therapies for rare diseases.
• Market EXONDYS 51 and VYONDYS 53 for treating Duchenne muscular dystrophy.
• Innovate through advanced exon-skipping technology to address genetic mutations.
• Collaborate with leading institutions for research and development.
• Expand product pipeline with candidates targeting various muscular dystrophies.
• Focus on addressing significant unmet medical needs in genetic disorders.

How Does SRPT Make Money?

• Generate revenue through the sale of FDA-approved therapeutics for rare diseases.
• Leverage partnerships and collaborations to enhance research and development.
• Invest in clinical trials to advance pipeline candidates towards commercialization.
• Utilize innovative technologies to develop unique treatment modalities.
• Focus on niche markets with high unmet medical needs for sustainable growth.

What Industry Does SRPT Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in genetic therapies and an increasing focus on rare diseases. The global market for gene therapies is projected to reach $13.3 billion by 2026, with a CAGR of 28.6%. Sarepta Therapeutics, Inc. is well-positioned within this landscape, focusing on RNA-targeted therapies for rare genetic disorders. The competitive landscape includes companies like ImmunityBio, Inc. (IBRX), Cogent Biosciences, Inc. (COGT), and Beam Therapeutics Inc. (BEAM), each vying for market share in the lucrative rare disease segment. Sarepta's innovative approach to DMD and its established product portfolio provide a competitive edge in a rapidly evolving market.

Who Are SRPT's Key Customers?

• Patients diagnosed with Duchenne muscular dystrophy and other rare diseases.
• Healthcare providers and specialists in genetic disorders.
• Research institutions and collaborators in drug development.
• Payers and insurance companies involved in reimbursement for therapies.
• Advocacy groups and organizations focused on rare disease awareness.

Over the past six months, Sarepta Therapeutics insiders filed 14 SEC Form 4 transactions — 4 sales and 10 purchases. On net that is roughly 3.0M shares acquired (about $37.6M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Sarepta Therapeutics

Revenue for Sarepta Therapeutics came in at $401.3M during Q2 FY2026, a 45.1% contraction versus the preceding quarter. The company recorded a net loss of $4.9M, with diluted EPS of $-0.05. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, SRPT averaged $-0.46 in diluted EPS.

SRPT Valuation & Market Position

With a $2.17B market cap, Sarepta Therapeutics sits in the mid-cap segment of the market. Analyst price targets span from $14.00 to $35.00, with a consensus of $24.43. At the current price of $20.52, that implies approximately 19% upside potential. Relative to its peer group, SRPT's quantitative score of 25/100 is below the peer average of 78/100.

Return on equity for Sarepta Therapeutics stands at -10.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.9%, the inverse of the P/E and a quick read on earnings relative to price.

Sarepta Therapeutics's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.01 places it in the distress zone, a signal of elevated financial risk.

Sarepta Therapeutics has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 12.3% above estimates on average.

Company Profile

Sarepta Therapeutics operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Michael E. Severino. SRPT has traded publicly since 1997.

SRPT Financials

SRPT Latest News

SRPT Analyst Consensus

SRPT MoonshotScore

Sarepta Therapeutics Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources